The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis

Citation data:

BMC Cardiovascular Disorders, ISSN: 1471-2261, Vol: 8, Issue: 24, Page: online - approx 5-20pp

Publication Year:
2008
Usage 123
Abstract Views 119
Link-outs 4
Captures 42
Exports-Saves 31
Readers 11
Mentions 1
Blog Mentions 1
Social Media 3
Shares, Likes & Comments 2
Tweets 1
Citations 52
Citation Indexes 51
Clinical Citations 1
Repository URL:
https://research-repository.uwa.edu.au/en/publications/a0ace036-a1fc-4028-ba00-ea67fd5e42ca; http://ro.uow.edu.au/ihmri/801
PMID:
18803866
DOI:
10.1186/1471-2261-8-24
PMCID:
PMC2559819
Author(s):
Potter, Kathleen; Hankey, Gaeme J; Green, Daniel J; Eikelboom, John W. W; Jamrozik, Konrad; Arnolda, Leonard F
Publisher(s):
Springer Nature
Tags:
Medicine; Medicine and Health Sciences
Most Recent Tweet View All Tweets
Most Recent Blog Mention
article description
Background: Experimental and epidemiological evidence suggests that homocysteine (tHcy) may be a causal risk factor for atherosclerosis. B-vitamin supplements reduce tHcy and improve endothelial function in short term trials, but the long-term effects of the treatment on vascular structure and function are unknown.Methods: We conducted a sub-study of VITATOPS, a randomised, double-blind, placebo-controlled intervention trial designed to test the efficacy of long term B-vitamin supplementation (folic acid 2 mg, vitamin B-6 25 mg and vitamin B-12 0.5 mg) in the prevention of vascular events in patients with a history of stroke. We measured carotid intima-medial thickness (CIMT) and flow-mediated dilation (FMD) at least two years after randomisation in 162 VITATOPS participants. We also conducted a systematic review and meta-analysis of studies designed to test the effect of B-vitamin treatment on CIMT and FMD.Results: After a mean treatment period of 3.9 +/- 0.9 years, the vitamin-treated group had a significantly lower mean plasma homocysteine concentration than the placebo-treated group (7.9 mu mol/L, 95% CI 7.5 to 8.4 versus 11.8 mu mol/L, 95% CI 10.9 to 12.8, p <0.001). Post-treatment CIMT (0.84 +/- 0.17 mm vitamins versus 0.83 +/- 0.18 mm placebo, p = 0.74) and FMD (median of 4.0%, IQR 0.9 to 7.2 vitamins versus 3.0%, IQR 0.6 to 6.6 placebo, p = 0.48) did not differ significantly between groups. A meta-analysis of published randomised data, including those from the current study, suggested that B-vitamin supplements should reduce CIMT (-0.10 mm, 95% CI -0.20 to -0.01 mm) and increase FMD (1.4%, 95% CI 0.7 to 2.1%). However, the improvement in endothelial function associated with homocysteine-lowering treatment was significant in short-term studies but not in longer trials.Conclusion: Although short-term treatment with B-vitamins is associated with increased FMD, long-term homocysteine-lowering did not significantly improve FMD or CIMT in people with a history of stroke.